Business Context and Reporting Period
Company: Septerna, Inc. (SEPN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: Septerna is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company focuses on endocrinology, immunology/inflammation, and metabolic diseases. It completed its Initial Public Offering (IPO) in October 2024.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $1,075 | $151 |
| Net Loss | $(71,798) | $4,180 (Income) |
| Research & Development Expenses | $65,337 | $35,979 |
| General & Administrative Expenses | $16,561 | $9,722 |
| Cash, Cash Equivalents & Marketable Securities | $420,800 | $88,483 |
| Accumulated Deficit | $(118,374) | $(46,576) |
| Net Cash Used in Operating Activities | $(67,470) | $(38,723) |
Note: 2023 net income was driven by a one-time $47.6 million gain on the sale of a non-financial asset (IPR&D) to Vertex Pharmaceuticals. 2024 revenue is derived solely from research services.
Material Changes vs. Prior Period
- Capital Raise: Completed an IPO in October 2024, issuing 18.4 million shares at $18.00 per share, generating net proceeds of $302.8 million. Also completed the second tranche of Series B Convertible Preferred Stock financing in May 2024 ($74.9 million).
- Operating Loss: Reported a net loss of $71.8 million in 2024 compared to net income of $4.2 million in 2023. The reversal is primarily due to the absence of the 2023 asset sale gain and increased operational expenditures.
- R&D Spend: R&D expenses increased by $29.4 million (82%) year-over-year, driven by higher external costs, clinical trial expenses for the SEP-786 program, and increased headcount.
- Liquidity: Cash and marketable securities increased from $88.5 million to $420.8 million, providing a runway into early 2028.
Guidance, Outlook, and Material Events
- Program Discontinuation: In February 2025 (subsequent to period end), the company announced the discontinuation of its Phase 1 clinical trial for SEP-786 (oral PTH1R agonist for hypoparathyroidism) following two unanticipated severe events of elevated unconjugated bilirubin. The company plans to advance a next-generation candidate from a different chemical series.
- Pipeline Progress:
- SEP-631: Oral MRGPRX2 negative allosteric modulator for Chronic Spontaneous Urticaria (CSU). Phase 1 initiation expected in 2025.
- TSHR Program: Advancing lead compounds for Graves' disease and Thyroid Eye Disease (TED).
- Incretin Programs: Advancing oral small molecule agonists for obesity and Type 2 Diabetes.
- Outlook: Management expects to continue incurring significant net losses for the foreseeable future as it advances clinical programs and operates as a public company.
- Risks: Key risks include the unproven nature of the Native Complex Platform, reliance on third-party manufacturers (including potential supply chain risks related to Chinese suppliers), and the high failure rate inherent in clinical drug development.
Investor Verification Checklist
- Cash Runway: Verify the $420.8 million cash balance and the management estimate of funding operations into early 2028.
- SEP-786 Discontinuation Impact: Assess the financial and strategic impact of halting the most advanced clinical program and the timeline for the next-generation PTH1R candidate.
- Third-Party Manufacturing: Review reliance on contract manufacturing organizations (CMOs), specifically any exposure to Chinese suppliers subject to the proposed BIOSECURE Act.
- Revenue Sustainability: Confirm that the $1.1 million in revenue is non-recurring (research services) and that no product revenue is expected until regulatory approval.
- Stock-Based Compensation: Note the $15.0 million in unrecognized stock-based compensation expense expected to be recognized over the next 2.8 years.